Professor Max C
@ProfCMaxi
Followers
485
Following
24K
Media
316
Statuses
1K
The more we learn about the power of IL-15 and the literature that exists decades ago (since 2010!) and never exploited is so exciting. Sepsis is responsible for over 200,000 deaths annually in the United States. We are planning a trial in community acquired pneumonia and
32
122
689
So $IBRX is buying the Dunkirk plant (400k+ sq ft in Buffalo, NY) for $1, with less than $2M left in lease payments to get there. ~$38M was already paid years ago to Athenex. Thatโs an incredible deal!
0
5
42
Great read. Very bullish for #ANKTIVA $IBRX
$IBRX The NCI suppressed the scientist who discovered NK cells. Now the FDA is fighting @DrPatrick who built a drug to activate them. In 1969, a scientist named Joseph Sinkovics drew his own blood, mixed it with a patient's cancer cells, and watched his lymphocytes kill them. He
0
10
35
My inspiration since 2008, when I picked up his chapter and his struggles of seminal discovery that was considered "laboratory artifact". When in fact, it can change mankind by this enlightenment. See Dr. Joseph G. Sinkovics. Change requires patience. But cancer is a war against
23
100
570
๐ข ๐๐๐๐ ๐๐: $IBRX ImmunityBio Secures $๐๐๐๐ Financing to Boost Global Expansion ๐ ๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ: โค ImmunityBio raises $๐๐๐ ๐ง๐จ๐ง-๐๐ข๐ฅ๐ฎ๐ญ๐ข๐ฏ๐ funding from Oberland Capital. โค Total committed capital under RIPA increases to $๐๐๐๐. โค
1
8
102
Capital in place.Approvals in 34 countries. Indication expansion globally in motion. Pipeline of combination trials cooking. Immunotherapy 2.0. Never give up.
At ImmunityBio, we continue to prioritize long-term growth and the advancement of our broader immunotherapy platform. This additional non-dilutive financing supports our effort to expand globally with the goal of improving outcomes for patients. Read more:
77
177
1K
At ImmunityBio, we continue to prioritize long-term growth and the advancement of our broader immunotherapy platform. This additional non-dilutive financing supports our effort to expand globally with the goal of improving outcomes for patients. Read more:
0
57
374
$IBRX They shorted the warning letter. Two weeks later: $100M non-dilutive financing. The founder converting his own debt into equity. 34 countries. $375M committed. Every domino that falls builds the empire and tightens the trap. What Just Happened $100M financing. $75M
12
31
187
Feels like the market is still anchored to dilution risk while this is trending toward strategic, potentially Saudi, non-dilutive capital. That gap is the trade. Long $IBRX
Strengthening the balance sheet. Recharging for global expansion. Stay tuned.
1
0
16
$IBRX (Immunitybio). This might be the most impressive and articulate analysis that I've seen in years about Anktiva, etc. Must Read! @DrPatrick
6
11
85
$IBRX The case for Anktiva's Accelerated Approval isn't about perfect data, it's about the right framework. ALC restoration isn't a post-hoc discovery; it's the inevitable pharmacodynamic output of an IL-15 superagonist, with 30 years of independent science behind it. The
1
8
42
Unleash #ANKTIVA and NK cell therapy for all cancer patients!
$IBRX โ FDA just made ANKTIVA a household name overnight. Once the public found out what it is, they want it more than anything. Awareness exploding! ๐ฅ๐ @DrPatrick @LoriMills4CA42
3
36
201
$IBRX - New Press Release ImmunityBio has confirmed that its pivotal Phase 2b trial, QUILT-2.005, is adequately powered to detect clinically meaningful differences between the ANKTIVA plus BCG combination and BCG alone for patients with BCG-naรฏve bladder cancer. This
2
19
153
Unleash #ANKTIVA, long $IBRX
Time to cut the red tape for all cancer patients! ANKTIVA activates NK cells and T cells to fight cancer naturally โ already FDA-approved for BCG-unresponsive bladder cancer with impressive long responses. Expand access to #ANKTIVA and NK cell therapies now so more patients can
0
0
2
$IBRX The NANT Leonardo system in brief details. What if cancer immunotherapy were built on a versatile immune platform rather than a single drug like Anktiva? I discuss how ImmunityBioโs NANT Leonardo system could begin with NK cells and progressively evolve into a comprehensive
This is how we build the 'World Bank of NK Cells' and make Immunotherapy 2.0 accessible to all of humanity. Our M-ceNK Phase 2 clinical trials ongoing with process development from over 60 healthy volunteers and patients with cancer completed to date. The future of growing
0
19
104
$IBRX Letโs be clear: The drug works.โจThe approvals are real. Revenue grew ~700% YoYโจwith continued acceleration. 33+ countries approved.โจGlobal expansion ongoing. A marketing-related FDA letterโจdoesnโt change science,โจdoesnโt remove approvals,โจand doesnโt stop global
$IBRX misleading ad, eh? On paper -sure .. Look at all the real life examples, Patients donโt have the time, and they will find ways eventually to get access to Anktiva if approvals donโt come soon Saudi will be the first gate, more to follow So, FDA (repeating myself here) ,
1
1
4
$IBRX (ImmunityBio) BTIG reiterates Buy, sees selloff as buying opportunity ๐ Analyst sees FDA warning as manageable compliance issue, with pullback creating opportunity ahead of 2H26 data.
0
1
2
@jiahanjimliu The FDA warning letter sounds scary in headlines but itโs a promotional compliance issue for $IBRX , not a safety or efficacy problem with ANKTIVA itself. They can fix their marketing materials, submit a remediation plan, and move on.
1
2
28
$IBRX TL;DR simplified: Anktiva is helping lung cancer patients, even when other immunotherapies already failed. In one study, 77% of patients got their immune cell counts back up after Anktiva. Those patients lived 16.2 months on average (some over 21 months). The ones who
@oshea9_harry @AscendingBio $IBRX In QUILT-3.055, if the overall ~14.1 month median overall survival (mOS) is the real story, why did the trial protocol (NCT03228667) prospectively list overall survival (OS) prolongation by ALC response as a co-primary endpoint? Focusing heavily on the pooled~14.1 month
0
3
36